Loading stock data…
Alvotech (ALVO)
$5.32-0.06 (-1.12%)
Pre-Market$5.30-0.02 (-0.38%)· Last close Sep 4
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alvotech in the Healthcare sector is trading at $5.32 with a market capitalization of $1.3B. Wall Street consensus targets $6.00 (5 analysts), implying a +12.8% move over the next 12 months. The stock is currently 42% below its 52-week high of $9.25, remaining 28.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +12.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $105.86M↓ | $166.57M↑ | $113.74M↓ | $173.24M↑ | $132.76M |
| Gross Profit | $59.78M↓ | $105.29M↑ | $78.74M↓ | $99.41M↑ | $67.32M |
| Operating Income | $9.67M↓ | $48.26M↑ | $1.31M↓ | $18.06M↑ | $10.58M |
| Net Income | $1.03M↑ | -$108.55M↓ | -$5.25M↓ | $32.04M↓ | $109.68M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.30B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
28.60%
Volume
Today's trading volume
535,401
Recent News
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% a
Has Alvotech (NasdaqGM:ALVO) Fallen Below Fair Value After Its Deal?
Alvotech stock has fallen about 50% over the past three years, yet the valuation checks currently lean cheap and the market is reacting positively to fresh licensing deals and regulatory progress. Over the past three years the share price is down about 50%, which means any case for owning Alvotech today rests heavily on a potential recovery from a deep drawdown. A recent licensing agreement with Lotus Pharmaceutical for two biosimilars and ongoing work toward U.S. approvals can support...
Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical
In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eight Asian markets, with potential consideration of up to approximately US$150 million plus ongoing supply revenues. The deal expands Alvotech’s access to oncology and hematology markets while keeping it in control of development, regulatory approvals, and global product supply. We’ll now examine...
Bank of America sees major upside in this biotech stock
A major Wall Street firm says a regulatory shift and coming launches could change the setup for one biosimilar developer.
Alvotech (ALVO) Gets New ‘Buy’ Reco. Should Investors Follow?
Alvotech (NASDAQ:ALVO) extended its winning streak to a 5th consecutive day on Monday, jumping 18.51 percent to finish at $5.25 apiece, after the Bank of America (BofA) raised its price target for the company. In its recent coverage, BofA initiated a buy recommendation on Alvotech shares with a price target of $7, amid the closure […]